Capreomycin
Antibiotics
- Drug class
- Antibiotics
- Availability
- See label
- Markets covered
- 1
- Products on record
- 1
Overview
Capreomycin is an active pharmaceutical ingredient in the Antibiotics group (J04AB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 1 | May 29, 2026 |
GBUnited Kingdom· MHRA
1 product
Uses
Actions:
Capreomycin is active against human strains of Mycobacterium tuberculosis. Frequent cross-resistance occurs between capreomycin and viomycin. Varying degrees of cross-resistance between capreomycin and kanamycin and neomycin have been reported.
No cross-resistance has been observed between capreomycin and isoniazid, aminosalicylic acid, cycloserine, streptomycin, ethionamide or ethambutol.
Indications:
Capreomycin should be used concomitantly with other appropriate antituberculous agents for the treatment of pulmonary infections caused by capreomycin susceptible strains of Mycobacterium tuberculosis when the primary agents (isoniazid, rifampicin, streptomycin and ethambutol) have been ineffective or cannot be used because of toxicity or the presence of resistant tubercle bacilli.
Drug interactions
Known interactions involving Capreomycin. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL450430108 · revised May 29, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.